X4 Pharmaceuticals (XFOR) Interest Expenses (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Interest Expenses came in at $2.2 million in Q4 2025, down 4.99% YoY from $2.3 million in Q4 2024, and down 3.01% on a QoQ basis from $2.3 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Interest Expenses (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Interest Expenses data on file, last reported at $2.2 million in Q4 2025.
- Quarterly Interest Expenses fell 4.99% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.9 million (up 1.27% YoY) and the FY2025 annual result came in at $214.2 million, up 15.83% from the prior year.
- Interest Expenses declined to $2.2 million in Q4 2025, from $2.3 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $2.4 million in Q3 2024 to a low of $189000.0 in Q4 2021.
- A 5-year average of $1.5 million and a median of $1.1 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 503.17% — and 2023, when it slumped 37.46%.
- Tracing XFOR's Interest Expenses over 5 years: stood at $189000.0 in 2021, then surged by 503.17% to $1.1 million in 2022, then plunged by 37.46% to $713000.0 in 2023, then jumped by 223.14% to $2.3 million in 2024, then slipped by 4.99% to $2.2 million in 2025.
- The last three Interest Expenses figures came in at $2.2 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | 38.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.49 Mn |
| Jun 30, 2026 | 38.49 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | 713,000.00 |
| Dec 31, 2023 | 713,000.00 |